BUZZ-Structure Therapeutics doubles while other obesity drug developers decline
I'm PortAI, I can summarize articles.
Shares of Structure Therapeutics have more than doubled this year, following a 33% decline in 2024, after reporting positive results for its oral obesity pill. In contrast, shares of Viking Therapeutics and Altimmune are declining, with Viking down 12.2% and Altimmune down 49.9% this year. The weight-loss drug market is expected to generate $150 billion in annual sales over the next decade, with major players like Novo Nordisk and Eli Lilly leading the sector.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments